debt_leverage_profile
Near-zero debt; pre-revenue biotech funded primarily by equity raises; a 20% rate rise has negligible direct debt-service impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal interest expense exposure; higher rates increase equity dilution cost and reduce biotech investor appetite, pressuring cash burn runway
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) API ingredient sourcing from North American hemp/cannabis processors; 2) specialized excipient suppliers concentrated in US/Canada with limited geopolitical chokepoint risk
Inferred
Agent_Inference
international_expansion_readiness
Revenues are near-zero internationally; sovereign currency devaluation risk is effectively nil at current commercial stage
Inferred
Agent_Inference
geographic_footprint
Primarily Canada/US operations; no material international revenue markets; negligible forex devaluation exposure currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Proprietary DehydraTECH processing is internal IP; no single external vendor represents >30% of input cost, though hemp-extract suppliers are limited
Inferred
Agent_Inference
business_model_type_primary
IP licensing and B2B technology platform; cloud infrastructure termination would disrupt admin/data ops but not core DehydraTECH delivery mechanism
Inferred
Agent_Inference
business_model_type_secondary
Contract research and licensing agreements with CPG/pharma partners; physical formulation IP is not cloud-dependent
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; DehydraTECH is a physical processing technology, not a software API; licensees face moderate switching cost due to reformulation requirements
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is IP licensing for physical bioavailability enhancement technology, not an investment contract or token scheme
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; no consumer data platform; clinical trial data handled under FDA/Health Canada frameworks with standard compliance protocols
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche bioavailability-enhancement IP licensor in fragmented cannabis/nutraceutical market with minimal market share concentration
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/milestone-based licensing and research contracts; negligible recurring subscription revenue at current stage
Inferred
Agent_Inference
monetization_vector
B2B IP licensing fees, research service contracts, and royalties on licensee product sales; no direct consumer monetization
Inferred
Agent_Inference
pricing_architecture
Cost-plus licensing with royalty upside; pricing vulnerable to licensee consolidation pressure and generic bioavailability alternatives eroding premium justification
Inferred
Agent_Inference
pricing_power_rating
Moderate; patented DehydraTECH provides differentiation but unproven commercial scale limits negotiating leverage with large pharma/CPG partners
Inferred
Agent_Inference
target_gross_margin_bracket
151.5% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider leakage; patented technology requires formal licensing; small licensee base means single non-renewal is material revenue risk
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth potential; IP licensing model can scale without proportional headcount increase; R&D staff expansion needed for new indication trials
Inferred
Agent_Inference
marginal_cost_of_growth
Very low marginal cost per additional licensee; incremental cost is primarily legal/regulatory support, not manufacturing or headcount
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics improve significantly; fixed IP development costs amortize across more licensees, but sales cycle length remains a constraint
Inferred
Agent_Inference
network_effect_present
No meaningful network effect; DehydraTECH value is standalone patent utility, not enhanced by number of users or licensees
Inferred
Agent_Inference
asset_efficiency_ratio
-285.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Low recession resistance; discretionary cannabis/nutraceutical licensee R&D budgets contract in downturns, delaying or canceling licensing agreements
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical and nutraceutical companies seeking enhanced cannabinoid bioavailability for product development; high concentration risk with few active licensees
Inferred
Agent_Inference
customer_segment_secondary
Cannabis CPG brands and wellness product manufacturers using DehydraTECH for consumer products; early-stage with limited revenue contribution
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
5.3% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001348362
High
SEC-EDGAR
ticker
LEXX
High
SEC-EDGAR